CTGCT - Centre of Excellence for the Technologies of Gene and Cell Therapy

关于生物医学过程机制的科学发现和修复疾病相关基因或破坏癌细胞的技术的发明是个性化医疗的重要支柱的基础。新的基因和细胞治疗技术卓越中心（CTGCT）将成为斯洛文尼亚第一个生物医学卓越中心，独特的方法将哺乳动物细胞合成生物学和免疫学相结合，为欧盟及其他地区的GCT和癌症免疫治疗开发新技术。CTGCT的目标是成为GCT跨学科突破性科学技术的领导者之一，并成为国际卓越研究，工业合作和公众参与的典范。CTGCT将获得基于技术的垂直整合的竞争优势，这些技术的进一步发展已经在国家化学研究所（SI）奠定了基础，并在高级合作伙伴伦敦大学学院（英国），乌得勒支大学医学中心（荷兰），Charité - Universitätsmedizin柏林（DE）和德累斯顿工业大学（DE）的专业知识和知识的支持下。在临床医生和患者组织的参与支持下，CTGCT将使研究成果转化为治疗应用，主要是神经和罕见遗传疾病和癌症免疫治疗，并建立制备GMP临床级治疗试剂的能力，这是目前有效转化的瓶颈。通过缩小翻译差距，CTGCT将促进斯洛文尼亚以及西巴尔干地区，东欧和其他地区的优秀研究和创新对健康的高度影响。它将加强科学能力和与合作伙伴和其他国外领先科学机构的长期合作，并改善GCT的可访问性。

Scientific discoveries on mechanisms of biomedical processes and invention of technologies to repair disease-related genes or destroy cancer cells represent the foundation of an important pillar of personalized medicine. The new Centre of Excellence for the Technologies of Gene and Cell Therapy (CTGCT) will be the first Centre of Excellence in biomedicine in Slovenia and unique with an approach combining mammalian cell synthetic biology and immunology to develop novel technologies for the development of GCTs and cancer immunotherapy in the EU and beyond. The aim of CTGCT is to become one of the leaders in the interdisciplinary breakthrough science technologies for GCT and a model for international research excellence, industrial collaboration and public engagement. CTGCT will gain a competitive edge based on the vertical integration of the technologies for whose further development the foundations have been laid at the National Institute of Chemistry (SI), and with support of expertise and knowledge of the advanced partners University College London (UK), University Medical Centre Utrecht (NL), Charité – Universitätsmedizin Berlin (DE) and Technical University Dresden (DE). Supported by the involvement of clinicians and patient organizations, CTGCT will enable translation of research achievementsinto therapeutic applications, primarily neurological and rare genetic diseases and cancer immunotherapy, and establish a capacity to prepare the GMP clinical grade therapeutic reagents, which is currently a bottleneck to effective translation. By bridging gap in translation, CTGCT will facilite high impact of excellent research and innovation on health in Slovenia as well as in the West Balkans, East Europe and beyond. It will strengthen scientific capabilities and long-term collaborations with partners and others leading scientific institutions from abroad, as well as improve accessibility of the GCTs.